Key result
Type 2 diabetes significantly increased the risk of cardiovascular events by 82% (HR 1.82) compared to no diabetes in patients receiving permanent pacemakers.
Why the study?
The difference in cardiovascular outcomes between patients with and without diabetes receiving permanent pacemaker treatment remained unexplored.
Does type 2 diabetes increase the risk of cardiovascular events in patients receiving permanent pacemakers?
Cohort (n=1,742)
No
Does type 2 diabetes increase the risk of cardiovascular events in patients receiving permanent pacemakers?
Hazard Ratio: 1.82 (95% CI 1.25–2.63)
Absolute Event Rate: 18.8% vs 12.3%
p-value: p=0.002
Diabetes is a significant independent risk factor for cardiovascular events, particularly heart failure hospitalization, in patients undergoing permanent pacemaker implantation.
T2D was associated with higher post-PPM CV event risk; extends prior associations but leaves open whether targeted interventions improve outcomes.
Background. Type 2 diabetes was associated with a higher risk for permanent pacemaker (PPM) treatment. The difference in cardiovascular outcomes between patients with and without diabetes receiving PPM treatment remains unexplored. Method. Between January 2003 and December 2017, 1742 patients receiving naïve PPM treatment comprised this retrospective cohort study and were categorized into two groups by the diagnosis of diabetes: group with diabetes ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>n</a:mi> <a:mo>=</a:mo> <a:mn>632</a:mn> </a:math> , 36.3%) and group without diabetes ( <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>n</c:mi> <c:mo>=</c:mo> <c:mn>1110</c:mn> </c:math> , 63.7%). The primary outcome was cardiovascular events including heart failure (HF) hospitalization and acute myocardial infarction (AMI). The secondary outcomes of this study included pacemaker infection, pacing-induced cardiomyopathy, cerebrovascular accident, cardiovascular mortality, and all-cause mortality. Propensity score matching (PSM) was applied to reduce selection bias between the study groups. Result. During a mean follow-up period of <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mn>7.8</e:mn> <e:mo>±</e:mo> <e:mn>4.8</e:mn> </e:math> years, 264 patients had a cardiovascular event. Before PSM, the incidence of cardiovascular events was higher in patients with diabetes compared to patients without diabetes (19.8% vs. 12.5%, <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>P</g:mi> <g:mo><</g:mo> <g:mn>0.001</g:mn> </g:math> ), and the incidences of pacing-induced cardiomyopathy, cardiovascular mortality, and all-cause mortality were all higher in patients with diabetes compared to patients without diabetes. After PSM, the incidence of cardiovascular events was higher in patients with diabetes compared to patients without diabetes (18.8% vs. 12.3%, <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mi>P</i:mi> <i:mo>=</i:mo> <i:mn>0.015</i:mn> </i:math> ). The incidence of HF hospitalization was higher in patients with diabetes compared to patients without diabetes (15.3% vs. 10.2%, <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mi>P</k:mi> <k:mo>=</k:mo> <k:mn>0.037</k:mn> </k:math> ), whereas the incidence of AMI did not differ between the two groups. Moreover, after PSM, patients with diabetes had higher cumulative incidences of pacing-induced cardiomyopathy and all-cause mortality compared to patients without diabetes. Conclusions. The prevalence of diabetes was over one-third of naïve PPM recipients of this cohort, and diabetes increased the risk of cardiovascular events in PPM recipients, especially for HF hospitalization.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) conducted a cohort in naïve permanent pacemaker (PPM) treatment (n=1,742). Type 2 diabetes vs. No type 2 diabetes was evaluated on Cardiovascular events including heart failure hospitalization and acute myocardial infarction (HR 1.82, 95% CI 1.25-2.63, p=0.002). Type 2 diabetes significantly increased the risk of cardiovascular events by 82% (HR 1.82) compared to no diabetes in patients receiving permanent pacemakers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: